van Opijnen Mark P, Nabuurs Rob J A, de Vos Filip Y F, Ramsoedh Mohini T R, Verhoeff Joost J C, Geurts Marjolein, Broekman Marike L D
Department of Neurosurgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands.
Department of Cell and Chemical Biology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands.
Brain Spine. 2024 Oct 10;4:103923. doi: 10.1016/j.bas.2024.103923. eCollection 2024.
The optimal treatment for recurrent glioblastoma patients remains not well-defined in international guidelines. On top of that, the availability of national guidelines is uncharted.
This study aimed to investigate the availability of national guidelines on the diagnosis and treatment of adult glioma throughout Europe, specifically focusing on recurrent glioblastoma.
Medical specialists with neuro-oncology expertise from all European countries were asked for the availability of official national guidelines. The primary outcome was whether guidelines provided recommendations on the treatment of recurrent glioblastoma in adults. Secondary outcomes included treatment specific recommendations and the role of clinical trials in the treatment of recurrent glioblastoma. The quality of the guidelines was assessed using the AGREE II instrument.
Of the 50 countries in Europe, information on guideline availability was obtained for 38 countries (76%). In twelve countries (24%) national guidelines on the diagnosis and treatment of glioma in adults exist. Focusing on recurrent glioblastoma, nine (18%) of the European countries provided any recommendations on the treatment of recurrent glioblastoma. In four (33%) guidelines it was explicitly stressed that there is currently no standard or evidence-based treatment for these patients.
National guidelines on the treatment of glioblastoma in adults are not uniformly available in Europe. In addition, and in contrast with international guidelines, the national guidelines differ profoundly in their recommendations regarding recurrent glioblastoma. This could contribute to unwanted practice variation. Efforts are needed to not only optimize, but also harmonize treatment for recurrent glioblastoma patients.
国际指南中对于复发性胶质母细胞瘤患者的最佳治疗方案仍未明确界定。除此之外，各国指南的可用性也尚不明确。
本研究旨在调查欧洲各国关于成人间质瘤诊断和治疗的国家指南的可用性，特别关注复发性胶质母细胞瘤。
向欧洲各国具有神经肿瘤学专业知识的医学专家询问官方国家指南的可用性。主要结果是指南是否提供了关于成人复发性胶质母细胞瘤治疗的建议。次要结果包括特定治疗建议以及临床试验在复发性胶质母细胞瘤治疗中的作用。使用AGREE II工具评估指南的质量。
在欧洲的50个国家中，获得了38个国家（76%）关于指南可用性的信息。在12个国家（24%）存在关于成人胶质瘤诊断和治疗的国家指南。聚焦于复发性胶质母细胞瘤，9个（18%）欧洲国家提供了关于复发性胶质母细胞瘤治疗的任何建议。在4个（33%）指南中明确强调，目前这些患者没有标准或基于证据的治疗方法。
欧洲各国并非都有关于成人胶质母细胞瘤治疗的国家指南。此外，与国际指南不同，各国指南在复发性胶质母细胞瘤的建议方面存在很大差异。这可能导致不必要的实践差异。不仅需要努力优化，还需要协调复发性胶质母细胞瘤患者的治疗。
